Advanced search
News (307)
Companies (1)
Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV h ...
Insiders
Mikael Dolsten holds the position of Chief Scientific Officer & Research President at Pfizer Inc. Dr. Dolsten is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In the past he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President for Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Senior Vice President for Wyeth Corp. and Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC. Dr. Dolsten received a doctorate from the University of Lund.
Mr. Mikael Lok is Head of Discretionary Portfolio Management at Crédit Agricole (Suisse) SA.
He was previously employed by Banque Martin Maurel and by HSBC France ex Crédit Commercial de France.
Mr. Lok studied at the University of Aix en Provence.
Mikael Claesson has worked as a Chief Executive Officer at Föreningen Svensk Handel since 2012.
No results for this search
- Stock Market
- Advanced search
- Mikael Dolsten